Background: The hypothesis that regular treatment aimed at achieving and maintaining asthma control is accompanied by reduced airway hyper-responsiveness (AHR) was investigated. Methods: Adult patients (PC 20 methacholine <8 mg/ml, FEV 1 % predicted !70%) received salmeterol/fluticasone propionate combination 50/250 mg bd (SFC250) for a 12-week run-in; those achieving well-controlled (WC) asthma were randomised to SFC250 (n Z 88) or SFC50/ 500 mg bd (SFC500) (n Z 90) for 24 weeks. AHR (PC 20 methacholine), asthma control, lung function, symptoms, exacerbations and safety were assessed. Results: During the 12 week run-in (SFC250), a greater than 1 doubling dose increase in PC 20 was observed. During randomised treatment, the increase in AHR was similar, and less than 1 doubling dose, for both groups (adjusted geometric mean PC 20 (mg/mL) at 24 weeks: SFC250: 2.796, SFC500: 2.802; p Z 0.992). Compared with SFC250, patients receiving SFC500 had a more rapid improvement in AHR (adjusted mean ratio to baseline respectively at week 4: 1.193 vs. 1.386; week 12: 1.395 vs. 1.672; p Z non-significant for both) and showed a greater response to treatment in patients with a low baseline PC 20 . Patients maintaining WC asthma were 72 (84%) and 64 (74%) in the SFC250 and SFC500 groups respectively. Both doses of SFC were well tolerated; only four exacerbations were reported, all in the SFC500 group. Conclusion: Regular treatment with SFC resulted in continuous improvement in AHR with maintenance of asthma control in the majority of patients. SFC500 showed a trend for a more * Corresponding author.
Introduction
Asthma is a chronic inflammatory disorder causing increased airway hyper-responsiveness (AHR) and episodic symptoms of wheezing, breathlessness, chest tightness and coughing. 1 Airway inflammation and AHR are frequently present when patients are asymptomatic 2e4 and there is no established relationship between asthma control, severity and level of inflammation; even patients with mild asthma show evidence of inflammation and airway remodelling. 5, 6 The aim of asthma management is to achieve and maintain asthma control by treating inflammation and relieving bronchoconstriction and symptoms. 1 Treatment guidelines recommend inhaled corticosteroids (ICS) as the most effective controller medication with the addition of a long-acting b 2 -agonist (LABA) in the form of a combination therapy being advocated as the preferred add-on therapy when symptoms are not adequately controlled on ICS alone. 1, 7 Despite these recommendations, most patients remain sub-optimally controlled. 8, 9 Salmeterol/fluticasone propionate combination (SFC) has been shown to significantly reduce inflammatory markers and AHR compared with fluticasone propionate alone, 10, 11 which may be related to the emerging evidence that LABAs potentiate the anti-inflammatory effects of ICS. 10, 12 In asthma, epithelial dysfunction may impair beta adrenoceptor function and thus contribute to AHR; and as LABAs have a beneficial impact on epithelial cell proliferation, this activity may help to protect against AHR. 13 In addition, the stepwise increase in dose in the Gaining Optimal Asthma ControL (GOAL) study showed that the majority of patients treated with SFC could achieve and maintain a composite, guideline-derived measure of asthma control. 14 The speed of response of individual control criteria was shown to vary, suggesting that assessment of one criterion may overestimate control, emphasising the importance of basing treatment changes on composite control. 15 The current study postulated, in line with Woolcock's model, 16 that regular treatment with SFC 50/250 mg bd (SFC 250), aimed at achieving and maintaining control of asthma, would be associated with a reduction in AHR. A higher dose of SFC, 50/500 mg bd (SFC500), was included as a comparator to determine if there was any additional benefit from an increased dose.
Methods Patients
Male or female patients, 18 years of age and older, with a history of asthma of at least six months, a PC 20 methacholine (PC 20 ) g <8 mg/ml and forced expiratory volume in 1 s (FEV 1 ) % predicted !70% were recruited from 33 centres in 10 European countries. All patients were seen on an outpatients basis. Patients were required to have received FP 100 mg bd to 250 mg bd or equivalent with or without a LABA for at least 4 weeks before the run-in period. Patients who had either been hospitalized for their asthma, had a respiratory tract infection, had received systemic corticosteroids within the last 4 weeks, or were current smokers were excluded. At the end of the 12 week run-in period, patients who had their asthma assessed as well-controlled (WC), based on assessment over the last 8 weeks, were eligible for randomisation. A week of GINA 1 -derived WC asthma as defined previously, was no night-time awakenings, no exacerbations, no emergency visits, no treatment-related adverse events enforcing a change in therapy, and having 2 out of 3 of: symptom score >1 h on 2 days, rescue b 2 -agonist use on 2 days and 4 occasions per week, and daily morning peak expiratory flow (PEF) !80% predicted. 14 
Study design
This multi-centre, stratified, double-blind, randomised, parallel-group study was conducted in 34 centres in 10 European countries. Following a 12 week open-label, run-in period, during which all patients received SFC250, those assessed as having WC asthma, were randomised to either continue treatment with SFC250 or to receive SFC500, for 24 weeks. Randomisation was stratified according to previous ICS dose (ICS dose FP 100 mg bd or equivalent or FP 250 mg bd or equivalent) and AHR at randomisation visit (PC 20 ! 2 mg/ml or < 2 mg/ml). Both treatments were supplied by GlaxoSmithKline (GSK) in identical Diskus devices to blind treatment. Patients were assessed at Weeks 4, 12 and 24 of treatment. The study was approved by a national, regional, or investigational centre ethics committee or institutional review board according to local laws and regulations. Written informed consent was obtained from each patient prior to any study-specific procedures.
Efficacy assessments
The primary endpoint was mean change in PC 20 h Symptom score: 1 was defined as 'symptoms for one short period during the day'; overall scale: 0 (none) to 5 (severe). predicted or the visit was within 4 weeks after the end of a short course of oral corticosteroids. An increase in PC 20 patients were asked to refrain from using short-acting bronchodilators for at least 6 h and study medication for 36 h prior to each visit. The highest of three PEF measurements were recorded each morning prior to taking any study or rescue medication. A score for asthma symptoms over the last 24 h was recorded each morning (scale from 0 representing 'no symptoms' to 5 representing 'symptoms so severe that patient could not go to work or perform normal activities').
Asthma exacerbations were monitored throughout the study and defined as a deterioration of asthma requiring administration of oral corticosteroids and/or deterioration in asthma requiring emergency room visit and/or admission to hospital.
Safety assessments
Safety was assessed by the monitoring of adverse events. Such data were collected throughout the study including serious adverse events and any events which, in the opinion of the clinician, were considered related to treatment.
Statistical analyses
Based on the number of patients required to detect a single doubling dose difference in PC 20 , with 90% power, a sample size of 60 evaluable patients per group was estimated. All analyses were based on the Intentionto-Treat population and significance testing used a twosided test conducted at the 0.05 significance level. Mean change from baseline in PC 20 at Week 24 was compared using an analysis of covariance (ANCOVA) model, allowing for effects due to treatment, baseline (randomisation) PC 20 , pre-study ICS dose, age, sex and country amalgamation. The proportion of patients with WC and TC asthma were compared using separate logistic regression models, and the change from baseline in pre-bronchodilator FEV 1 and FVC were analysed using ANCOVA. All efficacy data for PEF, asthma symptoms and rescue medication use, and all safety data were summarised. Tests for two-factor interactions between treatment and pre-study ICS dose, age, baseline PC 20 , country amalgamation and sex were performed (pre-defined significance level of 0.10).
Results

Patient characteristics
A total of 369 patients were screened for entry to the study of which 178 were randomised to double-blind treatment, 88 to SFC 250 and 90 to SFC500 (Fig. 1) . The two groups were well matched both demographically and for baseline lung function and symptom scores. Values were consistent with the randomisation of patients with WC asthma (Table 1) . Baseline (end of run-in) values for PEF and FEV 1 were slightly higher in the SFC500 group, as was baseline mean PC 20 (SFC500: 1.77 mg/mL; SFC 250: 1.48 mg/mL) ( Table 1) Efficacy assessments Run-in During the 12 week run-in period (treatment SFC250), there was a greater than 1 doubling dose increase in PC 20 in both groups: SFC250 increase from 0.64 mg/mL to 1.48 mg/mL; SFC500 increase from 0.67 mg/mL to 1.77 mg/mL (Table 1 , Fig. 2 ). Mean PEF and FEV 1 also increased during the run-in period (Table 1) .
Randomised treatment period PC 20 methacholine During the 24 week randomised treatment period PC 20 increased in both treatment groups with a less than 1 doubling dose increase observed in both groups (end of runin baseline to week 24 geometric mean: 1.62e2.80 mg/mL in the SFC250 group and 1.83e2.80 mg/mL in the SFC500 group, p Z 0.992) ( Table 2 , Fig. 2 ). However over the entire SFC treatment period (including run-in), a greater than two-fold improvement in AHR was observed in both groups. At the randomisation visit (end of run-in) 11 (13%) patients in the SFC250 group and 15 (17%) patients in the SFC500 group demonstrated AHR within the normal range (>8 mg/ mL). At subsequent visits, the number of patients with a PC 20 >8 mg/mL for SFC250 and SFC500 respectively: Week 4: 15 (17%) and 19 (21%); Week 12: 18 (20%) and 23 (26%); Week 24: 23 (26%) and 20 (22%).
For both groups, a faster improvement in PC 20 was observed in the first 12 weeks of randomised treatment followed by a smaller improvement from week 12 onwards (Fig. 2) . Compared with SFC250, a more rapid improvement was observed with SFC500, evidenced by a greater PC 20 adjusted geometric mean ratio to baseline at weeks 4 and 12 of treatment, although these differences were not statistically significant (Table 2) .
A significant interaction with treatment and baseline PC 20 was observed (p Z 0.047), the model estimating that patients who started with a lower baseline PC 20 had a better treatment response to the higher dose of SFC than those who started with a higher baseline PC 20 (Fig. 3) .
Secondary efficacy assessments
The results for secondary efficacy assessments are summarised in Table 3 . Over the last eight weeks of randomised treatment, the majority of patients in both groups maintained their WC asthma status with no significant difference between groups in the odds of maintaining WC asthma vs losing WC status (Odds Ratio SFC500 to SFC250: 0.58; 95% CL: 0.23, 1.43; p Z 0.235). Approximately a quarter of patients in each group achieved Totally Controlled asthma (meaning no clinical symptoms) over the last 8 weeks of treatment.
Patients assessed as not WC over the last 8 weeks of treatment showed less improvement in PC 20 (Fig. 4) .
There was a small difference between treatment groups in change in FEV 1 over treatment in favour of the SFC500 group (treatment difference 80 mL, p Z 0.048) ( Table 3) . Figure 1 Subject flow through the study. SFC250 Z salmeterol/fluticasone propionate combination 50/250 mg bd, SFC500 Z salmeterol/fluticasone propionate combination 50/500 mg bd, w/d Z withdrawn, e/c Z entry criteria. a Provocative concentration of methacholine causing forced expiratory volume in 1 s (FEV 1 ) to fall by 20% from post-saline baseline; SFC250 Z salmeterol/fluticasone propionate combination 50/250 mg bd, SFC500 Z salmeterol/fluticasone propionate combination 50/ 500 mg bd; SD Z standard deviation; CV Z coefficient of Variation.
Other minor changes in lung function indices and asthma symptoms were observed and were similar in both treatment groups.
During treatment very few exacerbations were reported. No patients in the SFC250 group had an exacerbation and four patients in SFC500 group each had one exacerbation. Of these, none resulted in hospitalization and three required treatment with oral corticosteroids.
Safety assessments
Overall, both doses of SFC were well tolerated with a similar proportion of patients reporting an adverse event in each group: 39 (44%) patients in the SFC250 group and 36 (40%) patients in the SFC500 group. Nasopharyngitis was the most commonly reported event in both groups (16% and 13% respectively). The incidence of serious adverse events and drug-related events was very low for both treatment groups.
Discussion
This study showed that, in adult patients with wellcontrolled asthma, treatment with SFC250 or SFC500 for 24 weeks resulted in a continuous improvement in AHR together with maintenance of asthma control in the majority of patients. These results are important as they support the view that a strategy based on regular and continued treatment with SFC, during which control is achieved and maintained, can contribute to a potential change in asthma severity, making a valid contribution to the concept that sustained treatment may result in sustained improvement of disease characteristics.
These results reinforce the importance of the timecourse for changes in AHR and show that this is the case even for patients who appear to have clinically controlled asthma. Although during randomised treatment the increase in PC 20 was less than 1 doubling dose, when the run-in is considered, a greater than two-fold improvement in PC 20 was demonstrated over 9 months. In a study evaluating the effect of high dose FP (750 mg bd), Ward et al 4 also showed that the time-course for improvement in spirometry, inflammation, airway remodelling and AHR was Z salmeterol/fluticasone propionate combination 50/500 mg bd. Y-axis is on the log scale. c Baseline over weeks À8 to À1; WC Z well-controlled; TC Z totally controlled; FEV 1 Z forced expiratory volume in 1 s; SFC250 Z salmeterol/fluticasone propionate combination 50/250 mg bd, SFC500 Z salmeterol/fluticasone propionate combination 50/ 500 mg bd; FVC Z forced vital capacity; PEF Z peak expiratory flow; SD Z standard deviation.
inflammation compared with a strategy based on guidelines alone. 19 However, Koenig et al. showed that, for most patients, improvement in AHR was maintained when a treatment strategy aimed at controlling clinical parameters alone was used. 20 The CATO study group found, in a group of moderate asthmatic children, that a treatment strategy guided by AHR showed no benefits in terms of symptom-free days but produced a better long-term outcome on FEV 1 , particularly in a sub-group exhibiting low symptom scores but with associated AHR. 21 Therefore, current treatment guidelines, based on symptoms and lung function alone, could result in anti-inflammatory treatment being stepped down too early in patients with persisting AHR in the absence of symptoms. A recent American Thoracic Society/European Respiratory Society Task Force identified the need to consider the relationship between control, severity and phenotypes in the context of treating asthma and assessing future risk. The authors suggested that characterizing populations by their phenotype can provide important additional information to the assessment of current clinical control, 22 and the findings of our study are consistent with this view.
The results of our study concur with the findings of a one year study by Lundback et al. showing that regular treatment with SFC resulted in significantly fewer exacerbations and greater improvements in AHR compared with treatment with monotherapy with either FP or salmeterol.
11 A subsequent, two year open extension showed that clinical control could be maintained over three years following physician-driven treatment changes: 73% patients were treated with SFC to maintain control compared with FP alone (21%) or salmeterol alone (5%). AHR continued to improve over the three years. 23 The results are also consistent with the GOAL study, demonstrating that regular treatment with SFC results in achieving and maintaining clinical control.
14 In our study, the benefits on asthma control appear to be related more to the regular use of treatment rather than the dose used. The statistically significant difference in FEV 1 in favour of the high dose group was not considered clinically significant. No significant benefit of the increased dose was observed in this study for PC 20 which concurs with the findings of Reddel et al. who demonstrated, in patients with poorly controlled asthma, that a daily dose of 1600 mg budesonide resulted in optimal control in most patients with no additional benefit derived from a starting dose of 3200 mg 24 However, in our study an interesting interaction between treatment and baseline PC 20 was investigated and indicated that patients with a lower baseline PC 20 showed a better response to the higher dose of SFC. In addition, the improvements in the SFC500 group appeared to be achieved more rapidly, as evidenced by a higher, albeit non-significant, PC 20 at weeks 4 and 12 of treatment. A more rapid improvement in AHR was also observed by the Reddel group during the first 8 weeks of treatment with budesonide 3200 mg daily compared with 1600 mg daily. 24 Therefore a sub-group of patients with a low PC 20 may benefit the most from a higher starting dose of SFC.
AHR is a marker of the natural history or severity of the disease rather than a criteria for control (long term vs. short term). 22 The importance of measuring bronchial responsiveness was also demonstrated by the SAPALDIA group who showed that, in formerly asymptomatic patients, AHR was a risk factor for accelerated decline in FEV 1 and development of asthma. 25 Similarly, Limb et al. demonstrated that factors in childhood that could identify individuals at risk for irreversible lung function deficits in adulthood included abnormal spirometry, low PC 20 and duration of asthma. 26 The number of exacerbations reported was higher in the SFC500 group compared with SFC 250 (four vs. none respectively), although a treatment duration of 24 weeks may be considered too short to gather meaningful data on exacerbations. However, this rate is very low and consistent with the low rates of exacerbations reported in other studies with SFC. 14, 27 The overall incidence of serious adverse events, drug-related events and withdrawals due to events was very low, and no safety issues or significant differences between treatments were identified.
In conclusion, this study showed that regular treatment with SFC resulted in continuous improvement in AHR with maintenance of asthma control in the majority of patients. SFC500 showed a trend for a more rapid improvement in AHR and resulted in greater improvements in patients with a lower baseline PC 20 . Notably, changes in AHR as a marker of disease modification takes longer than clinical control, and studies are needed to identify the appropriate time to initiate step-down therapy. W. Pieters, R. Schnorr, K. Venho. Thanks are also extended to Marc Poterre for his input into the original concept and design of the study and to Kate Hollingworth for editorial support in the form of developing a draft outline and first draft, assembling tables and figures and collating author comments (funded by GSK). All authors were involved in the interpretation of the results and the decision to submit the paper for publication.
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